PubMed Health⌕ Search

Biomedical subjects

Robert Mansberg

Publications and source records attributed to Robert Mansberg.

At least 19 recordsLinked to original sources
PubMed2005

Paravertebral infection (phlegmon) demonstrated by FDG dual-head coincidence imaging in a patient with multiple malignancies.

A 66-year-old woman was referred for a bone scan to assess back pain on a background of breast cancer, melanoma, and rheumatic heart disease. The scan appearance was suspicious for a localized soft tissue neoplasm. An FDG coincidence positron emission tomography (PET) study demonstrated a large FDG-avid soft tissue abnormality. Staphylococcus aureus was isolated from a subsequent needle biopsy. This case illustrates the use of FDG-PET in infection imaging, as well as demonstrating the potential pitfalls in nuclear oncology. Because FDG is not tumor-specific, accumulation in benign lesions may give rise to false-positive results despite a high pretest probability for malignancy.

Aged↗
PubMed2005

Symmetric bony involvement of the lower extremities with lymphoma demonstrated on gallium scintigraphy.

Primary or secondary lymphoma of the bone is uncommon. The sites of bony involvement include, in decreasing order of frequency, the spine, long bones, pelvis, ribs, and skull. A 66-year-old man with an atypical lineage of B-cell non-Hodgkin lymphoma is presented. The unusual initial presentation of the lymphoma included symmetric bony involvement of bilateral tibiae and the distal right femur, demonstrated on gallium-67 scintigraphy. The patient subsequently demonstrated resolution of the gallium-avid disease after treatment with fludarabine, cyclosporine, and ATG. This case also demonstrates the limitations of plain radiograph and the usefulness of MRI in the diagnosis of bony lymphoma.

Aged↗
PubMed2005

Thyroid dysfunction during interferon alpha therapy for chronic hepatitis C.

Interferon-alpha therapy is well known to induce a wide range of thyroid dysfunction. A 22-year-old woman with chronic hepatitis C developed overt hyperthyroidism while on interferon-alpha and ribavirin therapy. Tc-99m thyroid scintigraphy demonstrated virtually absent tracer uptake consistent with subacute thyroiditis. Ten months after starting antiviral therapy, overt hyperthyroidism recurred. Repeat thyroid scintigraphy revealed diffusely increased tracer uptake throughout the thyroid gland consistent with Graves disease. This is an unusual case of 2 forms of hyperthyroidism-confirmed scintigraphically and occurring in the same patient over time while on interferon-alpha therapy.

Adult↗
PubMed2005

Solitary plasmacytoma of bone: an unusual cause of severe sacral pain in a young man.

A 35-year-old man presented with insidious onset of severe sacral pain. Plain radiography, computed tomography, and magnetic resonance imaging revealed a large, locally invasive mass within the sacrum. Skeletal scintigraphy showed marked hyperemia and minimal peripheral osteoblastic activity of the sacral mass. An F-18 FDG PET study was performed for further assessment and clinical staging. The mass demonstrated high glucose avidity consistent with a high-grade tumor. Histologic examination confirmed the lesion to be a plasmacytoma. Solitary plasmacytoma of bone occurs predominantly in older patients involving the axial skeleton. This case is interesting in view of the large dimension, sacral involvement, the young age of the patient, and the appearance of this lesion across multiple imaging modalities.

Adult↗
PubMed2002

The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.

"Thyroid stunning" from diagnostic iodine-131 imaging prior to ablative therapy with (131)I for well-differentiated thyroid carcinoma has been well reported, but documentation of the effect on clinical outcome is sparse. The purpose of this retrospective study was to investigate the clinical effects of stunning. The outcome of (131)I ablative therapy in a group of patients ( n=36) who had diagnostic scans using 185 MBq (5 mCi) of (131)I was compared with that in a group ( n=36) who had diagnostic scans using 740 MBq (20 mCi) of (123)I. Patients were imaged at least 4 weeks after near-total thyroidectomy, prior to their first (131)I ablative therapy. Follow-up imaging was performed every 3-6 months, and further (131)I treatment administered when indicated. A group of patients ( n=36) who proceeded directly to their first therapy dose without a diagnostic scan and were followed up with (123)I was compared with the group who did have a (123)I diagnostic scan prior to the first ablative therapy. The efficacy of therapy was evaluated using ablation of the thyroid, evidenced by absence of uptake in the thyroid bed on the diagnostic scan, as the endpoint. Only 47% of patients in the (131)I diagnostic group had the thyroid gland ablated after a single administration of (131)I therapy, compared with 86% in the (123)I diagnostic group ( P<0.005). Patients who had (131)I diagnostic scans required higher total (131)I therapeutic activity (6.7 GBq or 180 mCi) to ablate the thyroid gland than those in the (123)I diagnostic group (4.4 GBq or 119 mCi). There was no difference in outcome between the group who did and the group who did not have a diagnostic study with (123)I prior to their first ablative therapy. The difference in outcome between the (131)I and the (123)I diagnostic groups demonstrates that the efficacy of (131)I therapy is reduced subsequent to the use of 185 MBq of (131)I for diagnostic imaging. This indicates that the phenomenon of stunning is clinically significant and affects the outcome of therapy.

Adult↗